GCC sickle cell sizing splits into two numbers a factor of 15-20 apart, and the gap between them is a care-registration constraint, not a measurement error.
The epidemiology method sizes GCC sickle cell disease from carrier frequency: 6 to 7 percent in Saudi Arabia's Eastern Province and comparable rates in Bahrain and Oman imply an estimated 140,000 to 200,000 patients in Saudi Arabia alone, 200,000 to 250,000 across the GCC, among the highest per-capita burdens outside sub-Saharan Africa. National premarital screening, mandatory in Saudi Arabia since the mid-2000s, is measurably cutting new HbSS births by 15 to 20 percent a year, but that incidence decline barely dents a prevalent population this large for at least a generation. The registry method counts differently: NPHC's SCD programme, the largest single rare-disease group it manages by patient count, actively manages an estimated 8,000 to 10,000 KSA patients under a dedicated annual budget of SAR 200 to 350 million.
The gap between 8,000 to 10,000 and 140,000 to 200,000 is not a contradiction, it is a coverage finding. NPHC's active-management registry captures patients who clear a specific severity and documentation threshold, three or more vaso-occlusive crises a year, formally enrolled for chronic transfusion exchange or iron chelation at KFSH&RC, KAMC, or comparable centres. Hydroxyurea itself reaches only 30 to 40 percent of eligible patients, and structured adult haematology programmes exist only at a handful of flagship centres, so most of the prevalent population outside Eastern Province is diagnosed via newborn screening but managed within general internal medicine rather than NPHC's dedicated exceptional-access line. The 8,000 to 10,000-patient NPHC cohort is the near-term addressable opportunity reachable through the existing national-programme channel; the 140,000-to-200,000-patient prevalence estimate is the total burden a novel agent would need expanded primary-care distribution, not just NPHC registration, to reach.
GCC sickle cell sizing — epidemiology-based prevalence versus NPHC's actively-managed registry
| Sizing Method | Population Estimate | Source |
|---|---|---|
| Epidemiology-based (carrier-rate-adjusted, KSA) | 140,000–200,000 patients | Al-Qurashi MM, Eur J Haematol 2010; NPHC Saudi SCD programme 2022 |
| Epidemiology-based (carrier-rate-adjusted, GCC-wide) | 200,000–250,000 patients | Al-Salem AH et al., Saudi Med J 2019 |
| Registry-based (NPHC actively-managed) | 8,000–10,000 patients | NPHC SCD programme annual report 2022 |
| Hydroxyurea treatment rate | 30–40% of eligible patients | Saudi SCD programme HU adherence audit 2021 |
Sources: Al-Qurashi MM, Eur J Haematol 2010; NPHC SCD programme annual report 2022; Al-Salem AH et al., Saudi Med J 2019; Saudi MOH SCD programme evaluation; Saudi SCD programme HU adherence audit 2021.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NPHC registry enrolment criteria (documented VOC threshold, structured-centre referral)
- the carrier-rate-adjusted epidemiology methodology
- why the gap is a care-registration finding, not a data error
Delivers
- Premarital screening coverage and the 15-20%/year HbSS birth-reduction effect
- why incidence decline does not meaningfully shrink a prevalent population this large within a launch-planning horizon
Delivers
- Sensitivity ranking of every input
- why registration and structured-centre capacity outranks the carrier-rate assumption
- scenario ranges tied to expanded MOH primary-care distribution
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why NPHC registration and structured-centre capacity, not carrier-rate prevalence, determine the near-term addressable total
- Pressure-tested against the 8,000-10,000-vs-140,000-200,000 gap before the rest of the model is built out
- Carrier-rate data (Eastern Province 6-7%; Bahrain and Oman comparable) driving the 140,000-200,000 KSA estimate
- The premarital-screening effect on new HbSS births (15-20%/year reduction)
- NPHC's actively-managed cohort (8,000-10,000) and its enrolment criteria
- The SAR 200-350 million annual NPHC SCD budget this population implies
- Reconciling the registry-vs-epidemiology gap as a care-registration finding
- Hydroxyurea's 30-40% treatment rate as the connecting evidence
- NPHC registration/structured-centre capacity ranked above carrier-rate prevalence
- Scenario ranges tied to expanded MOH primary-care distribution
- The full triangulated model, re-runnable with your own assumptions
- The open sizing questions your team must close before the number is used in planning
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx market sizing model triangulates at least two independent methods, epidemiology-based and registry-based, before accepting a patient count. This is explicitly a sizing model (static patient count), distinct from a Patient Flow or forecasting model (dynamic revenue/uptake).
Sickle cell disease GCC sizing sources: Al-Qurashi MM, Eur J Haematol 2010, the NPHC SCD programme annual report 2022, Al-Salem AH et al., Saudi Med J 2019, the Saudi MOH SCD programme evaluation, and the Saudi SCD programme HU adherence audit 2021.
- Carrier-rate-adjusted KSA and GCC-wide prevalence verified against Al-Qurashi MM, Eur J Haematol 2010 and Al-Salem AH et al., Saudi Med J 2019
- NPHC's actively-managed patient count and budget verified against the NPHC SCD programme annual report 2022
- Hydroxyurea treatment rate verified against the Saudi SCD programme HU adherence audit 2021
Frequently asked questions
Commission this model
AXLRx delivers rare disease market sizing models built for forecasting and strategy teams sizing the GCC sickle cell disease opportunity. Custom model in 72 hours.
Specify your indication, market, and cohort definition.
AXLRx analyst confirms triangulation methods and comparator set before building.
Research-verified sizing model in 72 hours with optional analyst readout.